
    
      This clinical trial is a prospective, single-organ, phase II clinical trial to evaluate the
      efficacy of curative proton therapy for liver metastasis of colorectal cancer diagnosed
      histologically as adenocarcinoma. Patients who meet the selection criteria should be
      selected, signed for consent, and treated 5 times a week for 7200 cGy / 15 fractions alone
      for 3 weeks.
    
  